GV20 Therapeutics
Dr. Tengfei Ted Xiao is a Co-Founder and the Chief Technology Officer of GV20 Therapeutics. Ted founded GV20 Therapeutics in 2016, after he finished his postdoctoral research training in Myles Brown lab at Dana-Farber Cancer Institute (DFCI). He was a pioneer of building up a functional CRISPR screening platform at DFCI. His expertise includes cancer genomics, high throughput screening techniques and bioinformatics. In GV20, he leads teams to build an AI-based antibody screening platform and has discovered several novel targets for cancer immunotherapy.
This person is not in any offices
GV20 Therapeutics
1 followers
GV20 Therapeutics is the US branch of GV20 Oncotherapy. The company utilizes high throughput functional genomics and AI approaches to identify novel cancer immunology drug targets, and discover and develop effective antibody drugs in cancer. GV20's proprietary antibody drug discovery engine has helped establish a solid portfolio of immuno-oncology antibody drug candidates for cancer treatment.